MX2009006234A - Moduladores del canal de ion. - Google Patents

Moduladores del canal de ion.

Info

Publication number
MX2009006234A
MX2009006234A MX2009006234A MX2009006234A MX2009006234A MX 2009006234 A MX2009006234 A MX 2009006234A MX 2009006234 A MX2009006234 A MX 2009006234A MX 2009006234 A MX2009006234 A MX 2009006234A MX 2009006234 A MX2009006234 A MX 2009006234A
Authority
MX
Mexico
Prior art keywords
sup
compounds
hydrates
esters
pharmaceutically acceptable
Prior art date
Application number
MX2009006234A
Other languages
English (en)
Inventor
Andrew Fensome
Jeffrey Curtis Kern
Hormoz Mazdiyasni
William Jay Moore
Robert Zelle
Vincent P Galullo
Paul Will
Christopher Todd Baker
Jinsong Guo
Danielle Soenen
Edward George Melenski
Justin Kaplan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009006234A publication Critical patent/MX2009006234A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Las actuales enseñanzas proporcionan compuestos de la fórmula (I) (ver fórmula (I)) y sus sales farmacéuticamente aceptables, hidratos y ésteres, en donde Ar, R1, R2, R3, p, y X se definen aquí. Las actuales enseñanzas también proporcionan procesos para producir dichos compuestos y sus sales farmacéuticamente aceptables, hidratos y ésteres, y métodos para tratar una afección patológica o trastorno, o aliviar su síntoma, utilizando dichos compuestos que incluyen sus sales farmacéuticamente aceptables, hidratos y ésteres. Los compuestos pueden ser útiles en modular la actividad del canal de ión que incluye tratar una variedad de afecciones asociadas con la modulación anormal de uno o más canales de calcio activados por voltaje.
MX2009006234A 2006-12-11 2007-12-11 Moduladores del canal de ion. MX2009006234A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87410206P 2006-12-11 2006-12-11
PCT/US2007/087060 WO2008073929A1 (en) 2006-12-11 2007-12-11 Ion channel modulators

Publications (1)

Publication Number Publication Date
MX2009006234A true MX2009006234A (es) 2009-06-22

Family

ID=39247781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006234A MX2009006234A (es) 2006-12-11 2007-12-11 Moduladores del canal de ion.

Country Status (6)

Country Link
US (1) US20100267697A1 (es)
EP (1) EP2099754A1 (es)
JP (1) JP2010512415A (es)
CA (1) CA2672223A1 (es)
MX (1) MX2009006234A (es)
WO (1) WO2008073929A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
AU2008279447A1 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
US9751847B2 (en) 2010-10-14 2017-09-05 University Of Utah Research Foundation Methods and compositions related to neuroactive thiazoline compounds
KR101796391B1 (ko) * 2015-07-24 2017-11-09 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
WO2017018751A1 (ko) * 2015-07-24 2017-02-02 동국대학교 산학협력단 Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
WO2018135918A1 (ko) * 2017-01-23 2018-07-26 동국대학교 산학협력단 Blt 저해 활성을 갖는 화합물을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물
KR102010947B1 (ko) * 2017-01-23 2019-08-14 동국대학교 산학협력단 Blt 저해 활성을 갖는 화합물을 유효성분으로 포함하는 아토피 예방 또는 치료용 약학적 조성물
HRP20220790T1 (hr) * 2017-05-04 2022-09-16 Bayer Cropscience Aktiengesellschaft Derivati 2-{[2-(feniloksimetil)piridin-5-il]oksi}etanamina i srodni spojevi kao pesticidi, primjerice namijenjeni zaštiti bilja
AU2018356556A1 (en) * 2017-10-27 2020-05-07 Esteve Pharmaceuticals, S.A. New alcoxyamino derivatives for treating pain and pain related conditions
CN109336836A (zh) * 2018-11-23 2019-02-15 厦门大学 Carm1小分子抑制剂的化合物及用途
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1576841A (en) * 1977-01-22 1980-10-15 Beecham Group Ltd Substituted n-acyl phenylamine compounds having hypolipidaemic activity
US4521243A (en) * 1983-12-15 1985-06-04 Stauffer Chemical Company N-Carbonyl-N-(4-substituted benzyl)-4-chloroanilines
WO2005000285A2 (en) * 2003-06-13 2005-01-06 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS

Also Published As

Publication number Publication date
US20100267697A1 (en) 2010-10-21
CA2672223A1 (en) 2008-06-19
WO2008073929A1 (en) 2008-06-19
EP2099754A1 (en) 2009-09-16
JP2010512415A (ja) 2010-04-22

Similar Documents

Publication Publication Date Title
MX2009006234A (es) Moduladores del canal de ion.
MX2009006232A (es) Derivados de carboxamida como moduladores del canal de ion.
WO2008073461A3 (en) Ion channel modulators
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2007146165A3 (en) Bone plates with intraoperatively tapped apertures
UA94246C2 (ru) Производные индазола, которые ингибируют рецептор trpv1
GB2419096A (en) Bone plates with intraoperatively tapped apertures
WO2009060629A1 (ja) リドカインテープ剤
NZ590495A (en) Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2007115409A8 (en) Compositions and methods for modulating gated ion channels
PH12014502584A1 (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
TW200727899A (en) Method of treating abnormal cell growth
TNSN08406A1 (en) 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
AU2003240517A1 (en) Substituted pyrrolines as kinase inhibitors
EP4096671A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH
TW200504676A (en) Enumeration method for the link clock rate and the pixel/audio clock rate
MY140494A (en) Staged countercurrent oxidation
MX2007010007A (es) Aparato y metodo para la produccion de hidrogeno.
NO20065768L (no) Karbonsamid-opioidforbindelser
WO2008028141A3 (en) Raf inhibitor compounds and methods of use thereof
WO2004106296A3 (en) Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
MX2009008288A (es) Compuestos que inhiben la colinesterasa.
WO2010014257A3 (en) Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
MX2009006233A (es) Moduladores del canal de ion.
WO2009018065A3 (en) Novel glucokinase activators and methods of using same

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal